Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: A three-center double-blind placebo-controlled study

Koychev, Ivan, McMullen, Katrina, Lees, Jane, Dadhiwala, Rukiya, Grayson, Lois Elizabeth, Perry, Charlotte Louise, Schmechtig, Anne, Walters, James Tynan Rhys, Craig, Kevin J., Dawson, Gerard R., Dourish, Colin T., Ettinger, Ulrich, Wilkinson, Lawrence Stephen, Williams, Steven, Deakin, John Francis William and Barkus, Emma 2012. A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: A three-center double-blind placebo-controlled study. European Neuropsychopharmacology 22 (7) , pp. 469-481. 10.1016/j.euroneuro.2011.10.005

Full text not available from this repository.

Abstract

A number of compounds aimed at improving cognition in schizophrenia have failed to demonstrate efficacy in Phase 2 clinical trials. Translational studies using biomarkers in surrogate populations, such as schizotypy, could be used to assess the efficacy of novel compounds. In this study, we aimed to validate the sensitivity and inter-site reliability of cognitive biomarkers (working memory (N-back), spatial working memory (SWM) and verbal fluency (VF) tasks) to detect the schizotypy phenotype and its reversal by psychotropic drugs. Healthy volunteers scoring high or average on a schizotypal personality measure (122 in each group) were randomized to receive a single dose of risperidone, amisulpride, nicotine or placebo in a double-blind, between-subject design. We found evidence for a poorer performance on N-back and VF tasks in the high schizotypy group, replicating previous research. This effect was counteracted by amisulpride on N-back: it improved working memory in high schizotypy group but impaired the controls. A similar pattern was seen in SWM and VF. We interpret this finding in the light of the dopamine enhancing action of amisulpride when given in low doses. In contrast, risperidone impaired both groups and nicotine had a beneficial effect for the low baseline performers only. These effects were consistent across sites. These data demonstrates the utility of biomarkers in detecting the effect of schizotypy and its reversal by drugs that enhance dopamine and cholinergic function. Studies using similar design could help the early assessment of potential of compounds designed to improve cognition in schizophrenia.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Psychology
Medicine
Neuroscience and Mental Health Research Institute (NMHRI)
MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG)
Subjects: R Medicine > R Medicine (General)
R Medicine > RC Internal medicine > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry
Uncontrolled Keywords: Schizophrenia; Schizotypy; Biomarkers; Cognition; Amisulpride; Risperidone
Publisher: Elsevier
ISSN: 0924-977X
Last Modified: 10 Oct 2017 14:07
URI: http://orca.cf.ac.uk/id/eprint/24822

Citation Data

Cited 18 times in Google Scholar. View in Google Scholar

Cited 30 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item